ACAD Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 28.30%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $4,392,208.16

ACADIA Pharmaceuticals Insider Trading History Chart

ACADIA Pharmaceuticals Share Price & Price History

^$16.46

▲ +0.13 (0.80%)

As of 09/19/2024 01:45 PM ET

Days: 30 | 90 | 365

Who are Nvidia’s New Silent Partners?

From Weiss Ratings | Ad

Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.

I call these Nvidia’s “Silent Partners.”

ACADIA Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/19/2024	Brendan Teehan	COO	Sell	9,534	$15.28	$145,679.52	52,177
8/19/2024	Mark C. Schneyer	CFO	Sell	9,733	$15.28	$148,720.24	43,735
8/19/2024	Stephen R. Davis	CEO	Sell	31,747	$15.28	$485,094.16	186,555
6/10/2024	Mark C. Schneyer	CFO	Sell	975	$14.79	$14,420.25	34,564
5/2/2024	Brendan Teehan	COO	Sell	3,477	$16.94	$58,900.38	42,133
5/2/2024	James Kihara	Insider	Sell	1,326	$16.94	$22,462.44	14,370
5/2/2024	Mark C. Schneyer	CFO	Sell	3,503	$16.94	$59,340.82	32,053
5/2/2024	Stephen R. Davis	CEO	Sell	11,427	$16.94	$193,573.38	155,231
4/8/2024	Brendan Teehan	COO	Sell	2,568	$17.87	$45,890.16	38,796
4/8/2024	James Kihara	Insider	Sell	1,790	$17.87	$31,987.30	13,100
4/8/2024	Mark C. Schneyer	CFO	Sell	2,716	$17.87	$48,534.92	28,742
4/8/2024	Stephen R. Davis	CEO	Sell	26,574	$17.87	$474,877.38	144,267
3/27/2024	Brendan Teehan	COO	Sell	5,140	$17.90	$92,006.00	36,340
3/27/2024	Mark C. Schneyer	CFO	Sell	5,434	$17.90	$97,268.60	26,183
3/27/2024	Stephen R. Davis	CEO	Sell	17,714	$17.90	$317,080.60	118,842
2/26/2024	Brendan Teehan	COO	Sell	624	$24.67	$15,394.08	31,432
2/26/2024	James Kihara	Insider	Sell	474	$24.67	$11,693.58	11,391
2/26/2024	Mark C. Schneyer	CFO	Sell	772	$24.67	$19,045.24	21,067
2/26/2024	Stephen R. Davis	CEO	Sell	5,577	$24.67	$137,584.59	101,890
1/8/2024	Austin D Kim	EVP	Sell	590	$29.96	$17,676.40	46,901
1/8/2024	Brendan Teehan	COO	Sell	731	$29.96	$21,900.76	30,949
1/8/2024	Stephen R. Davis	CEO	Sell	3,732	$29.96	$111,810.72	96,521
12/15/2023	James Kihara	Insider	Sell	2,000	$28.30	$56,600.00	11,025
11/20/2023	Brendan Teehan	COO	Sell	4,960	$22.64	$112,294.40	30,393
11/20/2023	James Kihara	Insider	Sell	1,985	$22.64	$44,940.40	13,025
11/20/2023	Mark C. Schneyer	CFO	Sell	5,108	$22.64	$115,645.12	20,486
10/6/2023	Austin D Kim	EVP	Sell	16,369	$21.96	$359,463.24	45,857
10/6/2023	Stephen R. Davis	CEO	Sell	51,563	$21.96	$1,132,323.48	89,131
9/15/2023	James Kihara	Insider	Sell	2,000	$25.88	$51,760.00	10,778
8/21/2023	Mark C. Schneyer	CFO	Sell	10,000	$29.00	$290,000.00	15,682
7/14/2023	Stephen R. Davis	CEO	Sell	100,000	$30.04	$3,004,000.00	36,695
7/11/2023	Stephen R. Davis	CEO	Sell	16,498	$25.00	$412,450.00	91,799
6/15/2023	James Kihara	Insider	Sell	2,000	$24.15	$48,300.00	9,144
6/12/2023	Laura Brege	Director	Sell	4,500	$24.87	$111,915.00	13,502
6/8/2023	Mark C. Schneyer	CFO	Sell	974	$25.02	$24,369.48	22,824
5/23/2023	Bros. Advisors Lp Baker	Director	Buy	209,053	$25.41	$5,312,036.73	38,811,515
5/17/2023	Brendan Teehan	COO	Sell	14,869	$22.50	$334,552.50	24,356
5/17/2023	James Kihara	Insider	Sell	5,947	$22.50	$133,807.50	11,144
5/17/2023	Mark C. Schneyer	CFO	Sell	15,310	$22.50	$344,475.00	21,905
5/1/2023	Austin D Kim	EVP	Sell	917	$21.18	$19,422.06	25,513
5/1/2023	Brendan Teehan	COO	Sell	548	$21.18	$11,606.64	9,487
5/1/2023	Stephen R. Davis	CEO	Sell	7,806	$21.18	$165,331.08	108,297
4/10/2023	James Kihara	Insider	Sell	523	$18.14	$9,487.22	5,197
4/6/2023	Austin D Kim	EVP	Sell	1,456	$18.16	$26,440.96	23,425
4/6/2023	Brendan Teehan	COO	Sell	1,751	$18.16	$31,798.16	8,468
4/6/2023	James Kihara	Insider	Sell	701	$18.16	$12,730.16	4,231
4/6/2023	Mark C. Schneyer	CFO	Sell	1,916	$18.16	$34,794.56	7,477
4/6/2023	Stephen R. Davis	CEO	Sell	8,582	$18.16	$155,849.12	100,478
2/24/2023	Austin D Kim	EVP	Sell	803	$18.78	$15,080.34	20,108
2/24/2023	Brendan Teehan	COO	Sell	461	$18.78	$8,657.58	5,195
2/24/2023	James Kihara	Insider	Sell	350	$18.78	$6,573.00	2,923
2/24/2023	Mark C. Schneyer	CFO	Sell	577	$18.78	$10,836.06	4,118
2/24/2023	Stephen R. Davis	CEO	Sell	3,851	$18.78	$72,321.78	91,727
1/12/2023	Laura Brege	Director	Sell	12,500	$18.25	$228,125.00
1/9/2023	Austin D Kim	EVP	Sell	589	$17.13	$10,089.57	18,697
1/9/2023	Brendan Teehan	COO	Sell	532	$17.13	$9,113.16	4,549
1/9/2023	Stephen R. Davis	CEO	Sell	3,904	$17.13	$66,875.52	84,633
11/21/2022	Srdjan R Stankovic	President	Sell	1,847	$15.07	$27,834.29	61,234
10/15/2022	Srdjan R Stankovic	President	Sell	1,326	$15.81	$20,964.06	56,831
10/15/2022	Stephen R. Davis	CEO	Sell	2,804	$15.81	$44,331.24	79,009
6/9/2022	Mark C. Schneyer	CFO	Sell	653	$17.91	$11,695.23	3,342
5/2/2022	Austin D Kim	EVP	Sell	894	$18.18	$16,252.92	16,742
5/2/2022	Brendan Teehan	COO	Sell	552	$18.18	$10,035.36	3,437
5/2/2022	Srdjan R Stankovic	President	Sell	2,865	$18.18	$52,085.70	55,188
5/2/2022	Stephen R. Davis	CEO	Sell	5,483	$18.18	$99,680.94	75,875
4/8/2022	James Kihara	insider	Sell	1,025	$27.05	$27,726.25	2,433
2/23/2022	Austin D Kim	EVP	Sell	782	$23.80	$18,611.60
2/23/2022	Brendan Teehan	COO	Sell	472	$23.80	$11,233.60
2/23/2022	James Kihara	Insider	Sell	359	$23.80	$8,544.20
2/23/2022	Srdjan R Stankovic	President	Sell	1,501	$23.80	$35,723.80
2/23/2022	Stephen R. Davis	CEO	Sell	3,928	$23.80	$93,486.40
11/22/2021	Srdjan R Stankovic	President	Sell	2,803	$19.01	$53,285.03
10/18/2021	Srdjan R Stankovic	President	Sell	1,338	$17.41	$23,294.58
10/18/2021	Stephen R. Davis	CEO	Sell	2,963	$17.41	$51,585.83

This Crypto Is Set to Explode in September

From Crypto 101 Media | Ad

With thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make HUGE gains. Now, I'm about to reveal the #1 crypto for September 2024.

Go here to get full details on this crypto now.

SEC Filings (Institutional Ownership Changes) for ACADIA Pharmaceuticals (NASDAQ:ACAD)

96.71% of ACADIA Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

ACADIA Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
9/16/2024	Point72 Asia Singapore Pte. Ltd.	4,538	$74K	0.0%	-72.5%	0.003%
9/5/2024	Sanctuary Advisors LLC	91,834	$1.54M	0.0%	N/A	0.056%
8/21/2024	Truist Financial Corp	50,006	$0.81M	0.0%	+16.0%	0.030%
8/21/2024	Stonepine Capital Management LLC	5,000	$81K	0.1%	N/A	0.003%
8/16/2024	Quarry LP	8,055	$0.13M	0.0%	+34.3%	0.005%
8/16/2024	Capital Impact Advisors LLC	24,540	$0.40M	1.1%	+153.4%	0.015%
8/16/2024	Algert Global LLC	534,143	$8.68M	0.3%	+50.7%	0.323%
8/16/2024	Cim Investment Management Inc.	15,082	$0.25M	0.1%	-19.2%	0.009%
8/15/2024	Scientech Research LLC	41,586	$0.68M	0.1%	N/A	0.025%
8/15/2024	Mackenzie Financial Corp	19,900	$0.32M	0.0%	-65.5%	0.012%
8/15/2024	The Manufacturers Life Insurance Company	462,078	$7.51M	0.0%	-60.6%	0.280%
8/15/2024	Millennium Management LLC	2,937,714	$47.74M	0.0%	+36.2%	1.778%
8/15/2024	D. E. Shaw & Co. Inc.	2,934,926	$47.69M	0.0%	+11.1%	1.776%
8/15/2024	Dark Forest Capital Management LP	32,910	$0.54M	0.1%	N/A	0.020%
8/15/2024	AQR Capital Management LLC	36,191	$0.59M	0.0%	-23.9%	0.022%
8/15/2024	Point72 Asia Singapore Pte. Ltd.	4,538	$74K	0.0%	-72.5%	0.003%
8/15/2024	Point72 Europe London LLP	50,600	$0.82M	0.1%	N/A	0.031%
8/14/2024	Squarepoint Ops LLC	848,441	$13.79M	0.0%	-14.2%	0.514%
8/14/2024	Fred Alger Management LLC	2,704,439	$43.95M	0.2%	+19.8%	1.637%
8/14/2024	Cubist Systematic Strategies LLC	666,578	$10.83M	0.1%	+47.6%	0.402%
8/14/2024	Marshall Wace LLP	2,774,353	$45.08M	0.1%	+431.1%	1.679%
8/14/2024	Bank of Montreal Can	96,225	$1.57M	0.0%	N/A	0.058%
8/14/2024	HighVista Strategies LLC	25,878	$0.42M	0.2%	N/A	0.016%
8/14/2024	ProShare Advisors LLC	26,626	$0.43M	0.0%	-20.7%	0.016%
8/14/2024	Profund Advisors LLC	56,555	$0.92M	0.0%	-8.7%	0.034%
8/13/2024	Thrivent Financial for Lutherans	78,292	$1.27M	0.0%	-4.1%	0.047%
8/13/2024	Sei Investments Co.	32,734	$0.53M	0.0%	-5.8%	0.020%
8/13/2024	Canada Pension Plan Investment Board	738,700	$12M	0.0%	+11.7%	0.447%
8/13/2024	Public Employees Retirement Association of Colorado	13,821	$0.23M	0.0%	-9.9%	0.008%
8/12/2024	XTX Topco Ltd	36,520	$0.59M	0.1%	N/A	0.022%
8/9/2024	Edgestream Partners L.P.	90,957	$1.48M	0.1%	+46.9%	0.055%
8/9/2024	Renaissance Technologies LLC	476,000	$7.74M	0.0%	-17.0%	0.288%
8/9/2024	Dimensional Fund Advisors LP	649,150	$10.55M	0.0%	N/A	0.393%
8/9/2024	Massachusetts Financial Services Co. MA	62,530	$1.02M	0.0%	+3.5%	0.038%
8/8/2024	Envestnet Asset Management Inc.	107,543	$1.75M	0.0%	+1.9%	0.065%
8/8/2024	Oppenheimer Asset Management Inc.	29,557	$0.48M	0.0%	+10.6%	0.018%
8/8/2024	Jupiter Asset Management Ltd.	1,060,840	$17.24M	0.2%	-33.9%	0.642%
8/8/2024	American Century Companies Inc.	73,148	$1.19M	0.0%	+76.7%	0.044%
8/8/2024	Rice Hall James & Associates LLC	742,935	$12.07M	0.7%	+11.8%	0.450%
8/7/2024	Headlands Technologies LLC	57,209	$0.93M	0.1%	+2,099.5%	0.035%
8/7/2024	Van Hulzen Asset Management LLC	91,485	$1.49M	0.1%	+18.4%	0.055%
8/6/2024	Quest Partners LLC	2,473	$40K	0.0%	-73.2%	0.001%
8/6/2024	Emerald Advisers LLC	808,831	$13.14M	0.6%	-51.0%	0.490%
8/6/2024	Acadian Asset Management LLC	6,884	$0.11M	0.0%	N/A	0.004%
8/6/2024	Emerald Mutual Fund Advisers Trust	558,849	$9.08M	0.5%	-55.3%	0.338%
8/6/2024	Los Angeles Capital Management LLC	50,969	$0.83M	0.0%	-24.5%	0.031%
8/5/2024	Arizona State Retirement System	29,983	$0.49M	0.0%	+2.2%	0.018%
8/5/2024	Victory Capital Management Inc.	94,422	$1.53M	0.0%	+18.4%	0.057%
8/3/2024	Hohimer Wealth Management LLC	159,133	$2.59M	0.6%	+828.8%	0.096%
8/3/2024	TD Asset Management Inc	23,296	$0.38M	0.0%	-78.0%	0.014%
8/1/2024	Rhumbline Advisers	186,500	$3.03M	0.0%	+1.2%	0.113%
8/1/2024	Natixis Advisors LLC	25,527	$0.42M	0.0%	+43.2%	0.015%
7/31/2024	Commonwealth Equity Services LLC	14,770	$0.24M	0.0%	+5.6%	0.009%
7/29/2024	Principal Financial Group Inc.	77,211	$1.26M	0.0%	-8.9%	0.047%
7/29/2024	Panagora Asset Management Inc.	661,870	$10.76M	0.1%	-5.6%	0.401%
7/26/2024	Allspring Global Investments Holdings LLC	108,838	$1.77M	0.0%	+85.0%	0.066%
7/26/2024	Bank of New York Mellon Corp	525,566	$8.54M	0.0%	+4.5%	0.318%
7/26/2024	AlphaCentric Advisors LLC	100,000	$1.63M	1.2%	+122.2%	0.061%
7/20/2024	Neo Ivy Capital Management	203,048	$3.30M	0.6%	N/A	0.123%
7/20/2024	China Universal Asset Management Co. Ltd.	19,410	$0.32M	0.0%	-38.7%	0.012%
7/20/2024	Hennion & Walsh Asset Management Inc.	102,477	$1.67M	0.1%	-28.3%	0.062%
7/16/2024	Diversified Trust Co	32,545	$0.53M	0.0%	+5.4%	0.020%
7/16/2024	M&G Plc	351,115	$5.62M	0.0%	+12.4%	0.213%
7/12/2024	SG Americas Securities LLC	99,476	$1.62M	0.0%	+17.1%	0.060%
7/11/2024	Wesbanco Bank Inc.	51,800	$0.84M	0.0%	+93.3%	0.031%
7/5/2024	DNB Asset Management AS	10,125	$0.17M	0.0%	N/A	0.006%
6/4/2024	DekaBank Deutsche Girozentrale	97,284	$1.75M	0.0%	+2.9%	0.059%
5/28/2024	Verity Asset Management Inc.	11,668	$0.22M	0.1%	N/A	0.007%
5/20/2024	Virtu Financial LLC	15,412	$0.29M	0.0%	N/A	0.009%
5/16/2024	California State Teachers Retirement System	108,822	$2.01M	0.0%	-5.2%	0.066%
5/15/2024	Price T Rowe Associates Inc. MD	3,999,550	$73.95M	0.0%	-22.8%	2.421%
5/15/2024	Lazard Asset Management LLC	26,213	$0.48M	0.0%	+208.6%	0.016%
5/14/2024	Nan Fung Group Holdings Ltd	102,984	$1.90M	1.8%	+243.5%	0.062%
5/14/2024	Advisors Asset Management Inc.	14,256	$0.26M	0.0%	+73.1%	0.009%
5/14/2024	EntryPoint Capital LLC	4,715	$87K	0.1%	-17.4%	0.003%
5/14/2024	CM Management LLC	40,000	$0.74M	0.6%	+33.3%	0.024%
5/14/2024	Shell Asset Management Co.	7,339	$0.14M	0.0%	+65.7%	0.004%
5/14/2024	Healthcare of Ontario Pension Plan Trust Fund	189,272	$3.50M	0.0%	-59.8%	0.115%
5/13/2024	Seven Eight Capital LP	151,171	$2.80M	0.3%	+128.3%	0.091%
5/11/2024	Covestor Ltd	2,032	$38K	0.0%	+70.5%	0.001%
5/11/2024	Hillsdale Investment Management Inc.	157,688	$2.92M	0.2%	+8.6%	0.095%
5/11/2024	Edgestream Partners L.P.	61,906	$1.15M	0.1%	+63.3%	0.037%
5/10/2024	Vanguard Group Inc.	13,298,541	$245.89M	0.0%	-0.7%	8.050%
5/10/2024	Jupiter Asset Management Ltd.	1,603,774	$29.65M	0.3%	+21.3%	0.971%
5/10/2024	M&G Plc	312,325	$5.62M	0.0%	N/A	0.189%
5/9/2024	State Board of Administration of Florida Retirement System	39,881	$0.75M	0.0%	+15.3%	0.024%
5/8/2024	ProShare Advisors LLC	33,583	$0.62M	0.0%	+10.0%	0.020%
5/8/2024	Russell Investments Group Ltd.	20,689	$0.38M	0.0%	+12.3%	0.013%
5/8/2024	Headlands Technologies LLC	2,601	$48K	0.0%	N/A	0.002%
5/7/2024	Sei Investments Co.	34,752	$0.64M	0.0%	+6.2%	0.021%
5/7/2024	Swiss National Bank	210,604	$3.89M	0.0%	+0.4%	0.127%
5/7/2024	Oppenheimer Asset Management Inc.	26,715	$0.49M	0.0%	-21.6%	0.016%
5/7/2024	SG Americas Securities LLC	84,956	$1.57M	0.0%	+246.7%	0.051%
5/3/2024	GSA Capital Partners LLP	111,394	$2.06M	0.2%	+730.9%	0.067%
5/2/2024	Mutual of America Capital Management LLC	66,930	$1.24M	0.0%	-5.0%	0.041%
5/2/2024	Nordea Investment Management AB	322,504	$5.94M	0.0%	-45.0%	0.195%
5/1/2024	Capstone Investment Advisors LLC	11,403	$0.21M	0.0%	N/A	0.007%
5/1/2024	BNP Paribas Financial Markets	120,145	$2.22M	0.0%	-47.7%	0.073%
5/1/2024	Mirae Asset Global Investments Co. Ltd.	76,792	$1.42M	0.0%	-10.5%	0.046%
4/30/2024	Privium Fund Management B.V.	148,400	$2.74M	0.7%	N/A	0.090%

Data available starting January 2016

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Today's Range

Now: $16.46

$16.37

$16.81

50 Day Range

MA: $16.86

$15.14

$19.14

52 Week Range

Now: $16.46

$14.55

$32.59

Volume

240,720 shs

Average Volume

1,730,434 shs

Market Capitalization

$2.72 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.4

Who are the company insiders with the largest holdings of ACADIA Pharmaceuticals?: ACADIA Pharmaceuticals' top insider investors include:
Bros Advisors Lp Baker (Director)
Stephen Davis (CEO)
Srdjan R Stankovic (President)
Brendan Teehan (COO)
Austin D Kim (EVP)
Mark C Schneyer (CFO)
James Kihara (Insider)
Laura Brege (Director)
Learn More about top insider investors at ACADIA Pharmaceuticals.
Who are the major institutional investors of ACADIA Pharmaceuticals?: ACADIA Pharmaceuticals' top institutional shareholders include:
Millennium Management LLC — 1.78%
D. E. Shaw & Co. Inc. — 1.78%
Marshall Wace LLP — 1.68%
Fred Alger Management LLC — 1.64%
Jupiter Asset Management Ltd. — 0.64%
Squarepoint Ops LLC — 0.51%
Learn More about top institutional investors of ACADIA Pharmaceuticals stock.
Which institutional investors are selling ACADIA Pharmaceuticals stock?: In the last quarter, ACAD stock was sold by these institutional investors:
Emerald Advisers LLC
The Manufacturers Life Insurance Company
Emerald Mutual Fund Advisers Trust
Jupiter Asset Management Ltd.
Squarepoint Ops LLC
Susquehanna International Group LLP
Renaissance Technologies LLC
TD Asset Management Inc
During the previous year, company insiders that have sold ACADIA Pharmaceuticals company stock include:
Bros Advisors Lp Baker (Director)
Stephen Davis (CEO)
Srdjan R Stankovic (President)
Brendan Teehan (COO)
Austin D Kim (EVP)
Learn More investors selling ACADIA Pharmaceuticals stock.
Which institutional investors are buying ACADIA Pharmaceuticals stock?: During the previous quarter, ACAD stock was purchased by institutional investors including:
Marshall Wace LLP
Millennium Management LLC
Dimensional Fund Advisors LP
Fred Alger Management LLC
D. E. Shaw & Co. Inc.
Cubist Systematic Strategies LLC
Neo Ivy Capital Management
Algert Global LLC